Business Insider

Rectify Pharma Announces Positive Functional Modulator RTY-694 as Development Candidate for Primary Sclerosing Cholangitis

RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flow The differentiated mechanism of a dual-targeted ABCB4/BSEP PFM ...
Business Insider

Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis

RTY-406 demonstrates significant improvements in disease relevant endpoints in a mouse model of primary sclerosing cholangitis (PSC) and proof of mechanism in non-human primates RTY-406 is in Phase 1 ...
NBC4 Columbus

Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025

Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate ...
FierceBiotech

Rectify's new lead candidate improves bile composition, reduces inflammation in mice with liver disease

Rectify Pharma calls its new lead candidate a "pipeline-in-a-pill" because of its potential to treat the underlying cause of multiple liver diseases. (iStock / Getty Images Plus) Rectify Pharma is ...
Yahoo Finance

Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and ...